Last reviewed · How we verify
NCT06727851: QIC_ERCP
ESGE-Quality Improvement in Endoscopy: ERCP
trial in Post-ERCP Acute Pancreatitis in 1,254 participants. Enrolling by invitation.
31 December 2025
Quick facts
| Lead sponsor | Universität Münster |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 1,254 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across Germany |
Conditions studied
- Post-ERCP Acute Pancreatitis — all drugs for Post-ERCP Acute Pancreatitis →
Sponsor
Universität Münster — full company profile →
Who can join
18 and older, any sex, with Post-ERCP Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of the present study is to compare the incidence of post-ERCP pancreatitis (PEP) before and after the implementation of the QIC-guideline in 2017: "Performance measures for ERCP and endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative".
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06727851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-ERCP Acute Pancreatitis
Currently open trials in the same condition.
- NCT07117318 — Rectal NSAIDs With/Without PD Stent for PEP Prevention · NA · recruiting
- NCT06260878 — Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis · Phase 4 · recruiting
- NCT05267379 — An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreati · recruiting
Other Universität Münster trials
Trials by the same sponsor.
- NCT07197307 — Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · Phase 2 · not yet recruiting
- NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
- NCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodyna · Phase 1 · completed
- NCT06021288 — Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI ) · NA · recruiting
- NCT06095713 — German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsid · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06727851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universität Münster
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06727851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing